N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl) heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists

Journal of Medicinal Chemistry

Volumn 52, Issue 8, 2009, Pages 2559-2570

  Newman, Amy Hauck ^a   Grundt, Peter ^a   Cyriac, George ^a   Deschamps, Jeffrey R ^c   Taylor, Michelle ^b   Kumar, Rakesh ^b   Ho, David ^b   Luedtke, Robert R ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^c NAVAL RESEARCH LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; BENZENE DERIVATIVE; CHLORINE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 4 RECEPTOR; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL] 3 HYDROXYBUTYL] 1H INDOLE 2 CARBOXAMIDE; PIPERAZINE DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENANTIOSELECTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PHARMACOPHORE; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; X RAY DIFFRACTION;

ALLOSTERIC SITE; BINDING SITES; BINDING, COMPETITIVE; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DRUG PARTIAL AGONISM; HUMANS; INDOLES; LIGANDS; PIPERAZINES; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D4; RECOMBINANT FUSION PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65249161020     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900095y     Document Type: Article

References (65)

1. Joyce, J. N.; Milian, M. J. Dopamine D-3 receptor antagonists as therapeutic agents. Drug Discovery Today 2005, 10 , 917-925.
2. Newman, A. H.; Grundt, P.; Nader, M. A. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J. Med. Chem. 2005, 11 , 3663-3679.
3. Heidbreder, C. A.; Gardner, E. L.; Xi, Z.-X.; Thanos, P. K.; Mugnaini, M.; Hagan, J. J.; Ashby, J. C. R. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res. Rev. 2005, 49 , 77-105.
4. 35S]thio) -triphosphate binding and antibody study. Mol. Pharmacol. 1999, 55 , 564-574.
5. Cussac, D.; Newman-Tancredi, A.; Pasteau, V.; Millan, M. J. Human dopamine D (3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. Mol. Pharmaco. 1999, 56 , 1025-1030.
6. Boeckler, F.; Gmeiner, P. The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neu-ropharmacological aspects. Pharmacol. Ther. 2006, 112 , 281-333.
7. Micheli, F.; Heidbreder, C. Selective dopamine D3 receptor antagonists. A decade of progress 1997-2007. Expert Opin. Ther. Pat. 2008, 18 , 821-840.
8. 3 receptor antagonist with high oral bioavailability and CNS penetration in the rat. J. Med. Chem. 2000, 43 , 1878-1885.
9. (b) Reavill, C; Taylor, S. G.; Wood, M. D.; Ashmeade, T.; Austin, N. E.; Avenell, K. Y.; Boyfield, I.; Branch, C. L.; Cilia, J.; Coldwell, M. C; Hadley, M. S.; Hunter, A. J.; Jeffrey, P.; Jewitt, F.; Johnson, C. N.; Jones, D. N. C; Medhurst, A. D.; Middlemiss, D. N.; Nash, D. J.; Riley, G. J.; Routledge, C; Stemp, G; Thewlis, K. M.; Trail, B.; Vong, A. K. K.; Hagan, J. J. Pharmacological actions of a novel, high-affinity, and selective human dopamine D-3 receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. 2000, 294 , 1154-1165.
10. Macdonald, G. J.; Branch, C. L.; Hadley, M. S.; Johnson, C. N.; Nash, D. J.; Smith, A. B.; Stemp, G.; Thewlis, K. M.; Vong, A. K. K.; Austin, N. E.; Jeffrey, P.; Winborn, K. Y.; Boyfield, I.; Hagan, J. J.; Middlemiss, D. N.; Reavill, C; Riley, G. J.; Watson, J. M.; Wood, M.; Parker, S. G.; Ashby, C. R. Design and synthesis of trans-3- (2- (4- ((3- (3- (5-methyl-1, 2, 4-oxadiazolyl)) phenyl) carboxamido) cyclo-hexyl) ethyl) -7-methylsulfonyl-2,3, 4, 5-tetrahydro-1H-3-benza-zepine (SB-414796) : A potent and selective dopamine D-3 receptor antagonist. J. Med. Chem. 2003, 46 , 4952-4964.
11. Mcheli, F.; Bonanomi, G.; Blaney, F. E.; Braggio, S.; Capelli, A. M.; Checchia, A.; Curcuruto, O.; Damiani, F.; Fabio, R. D.; Donati, D.; Gentile, G; Gribble, A.; Hamprecht, D.; Tedesco, G; Terreni, S.; Tarsi, L.; Lightfoot, A.; Stemp, G.; Macdonald, G.; Smith, A.; Pecoraro, M.; Petrone, M.; Perini, O.; Piner, J.; Rossi, T.; Worby, A.; Pilla, M.; Valerio, E.; Griffante, C; Mugnaini, M.; Wood, M.; Scott, C; Andreoli, M.; Lacroix, L.; Schwarz, A.; Gozzi, A.; Bifone, A.; Ashby, C. R., Jr.; Hagan, J. J.; Heidbreder, C. 1,2, 4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D (3) receptor antagonists. J. Med. Chem. 2007, 50 , 5076-5089.
12. Pilla, M.; Perachon, S.; Sautel, F.; Garrido, F.; Mann, A.; Wermuth, C. G.; Schwartz, J. C; Everitt, B. J.; Sokoloff, P. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D-3 receptor agonist. Nature (London) 1999, 400 , 371-375.
13. Beardsley, P. M.; Sokoloff, P.; Balster, R. L.; Schwartz, J. C. The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered. Behav. Charmacol. 2001, 12 , 1-11.
14. 3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J. Neurosci. 2002, 22 , 9595-9603.
15. Cervo, L.; Cocco, A.; Petrella, C.; Heidbreder, C. Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behavior in the rat. Int. J. Neuropsychopharmacol. 2006, 10 , 167-181.
16. Gilbert, J. G.; Newman, A. H.; Gardner, E. L.; Ashby, C. R.; Heidbreder, C. A.; Pak, A. C; Peng, X. Q.; Xi, Z. X. Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D-3 receptors. Synapse 2005, 57 , 17-28.
17. Xi, Z.-X, ; Newman, A. H.; Gilbert, J. G.; Pak, A. C.; Peng, X.-Q.; Ashby, C. A.; Gitajn, L.; Gardner, E. L. The novel dopamine D3 receptors antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug seeking behavior in rats. Neuropsychopharmacoloy. 2006, 31 , 1393-1405.
18. Xi, Z. X.; Gardner, E. L. Pharmacological actions of NGB 2904, a selective dopamine D-3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev. 2007, 13 , 240-259.
19. Spiller, K.; Xi, Z.-X.; Peng, X.-Q.; Newman, A. H.; Ashby, C. R.; Heidbreder, C; Gaal, J.; Gardner, E. L. The putative dopamine D3 receptor antagonists SB 277011A, NGB 2904 or BP 897 inhibit methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacoloey 2008, 196 , 533-542.
20. Collins, G. T.; Witkin, J. M.; Newman, A. H.; Svensson, K. A.; Grundt, P.; Cao, J. J.; Woods, J. H. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J. Pharmacol. Exp. Ther. 2005, 314 , 310-319.
21. Collins, G. T.; Newman, A. H.; Grundt, P.; Rice, K. C.; Husbands, S. M.; Chauvignac, C; Chen, J.; Wang, S.; Woods, J. H. In vivo D3 receptor selectivity of dopamine agonists and antagonists by analysis of yawning and hypothermia in rats. Psychopharmacology 2007, 193 , 159-170.
22. Martelle, J. L.; Claytor, R.; Ross, J. T.; Reboussin, B. A.; Newman, A. H.; Nader, M. A. Effects of two novel D-3-selective compounds, NGB 2904 [N - (4- (4- (2, 3-dichlorophenyl) piperazin-1-yl) butyl) -9H -fluorene-2-carboxamide] and CJB 090 [N - (4- (4- (2, 3-dichlorophe-nyl) piperazin-1-yl) butyl) -4- (pyridin-2-yl) benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 2007, 321 , 573-582.
23. Novi, F.; Millan, M. J.; Corsini, G. U.; Maggio, R. Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N -desmethylclozapine and preclamol at dopamine D (2L) receptors are modified by co-transfection of D (3) receptors: potential role of heterodimer formation. J. Neurochem. , 2007, 102 , 1410-1424.
24. Urban, J. D.; Clarke, W. P.; von Zastrow, M.; Nichols, D. E.; Kobilka, B.; Weinstein, H.; Javitch, J. A.; Roth, B. L.; Christopoulos, A.; Sexton, P. M.; Miller, K. J.; Spedding, M.; Mailman, R. B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 2007, 320 , 1-13.
25. Maggio, R.; Novi, F.; Rossi, M.; Corsini, G. U.; Millan, M. J. Partial agonist actions at dopamine D2L receptors are modified by co-transfection of D3 receptors: potential role of heterodimer formation. Parkinsonism Relat. Disord. 2008, 14 (Suppl. 2), S139-S144.
26. Paul, N. M.; Taylor, M.; Kumar, R.; Deschamps, J. R.; Luedtke, R. R.; Newman, A. H. Structure-activity relationships for a novel series of dopamine D2-like receptor ligands based on N - substituted 3-aryl-8-azabicyclo[3. 2.1]octan-3-ol. J. Med. Chem. 2008, 51 , 6095-6109.
27. Grundt, P.; Carlson, E. E.; Cao, J.; Bennett, C. J.; McElveen, E.; Taylor, M.; Luedtke, R. R.; Newman, A. H. Novel heterocyclic trans olefin analogues of N - (4-[4- (2, 3-dichlorophenyl) piperazin-1-yl]butyl) aryl-carboxamides as selective probes with high affinity for the dopamine D3 receptor. J. Med. Chem. 2005, 48 , 839-848.
28. Grundt, P.; Prevatt, K. M.; Cao, J.; Taylor, M.; Floresca, C. Z.; Choi, J. K.; Jenkins, B. G.; Luedtke, R. R.; Newman, A. H. Heterocyclic analogues of N - (4- (4- (2, 3-Dichlorophenyl) piperazin-1-yl) butyl) aryl-carboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. J. Med. Chem. 2007, 50 , 4135-4146.
29. (a) Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44 , 235-249.
30. (b) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23 , 3-25.
31. Beshore, D. C; Dinsmore, C. J. Preparation of ethyl 5-iodo-1 H -indole-2-carboxylate. Synth. Commun. 2003, 33 , 2423-2427.
32. Luedtke, R. R.; Freeman, R. A.; Boundy, V. A.; Martin, M. V.; Huang, Y. S.; Mach, R. H. Characterization of I-125-IABN, a novel azabi-cyclononane benzamide selective for D2-like dopamine receptors. Synapse 2000, 38 , 438-449.
33. Cambridgesoft ChemDraw Ultra , version 11.0; CambridgeSoft, Cambridge, MA, 2007.
34. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 2000, 43 , 3714-3717.
35. Hocke, C; Prante, O.; Lober, S.; Hubner, H.; Gmeiner, P.; Kuwert, T. Synthesis and radioiodination of selective ligands for the dopamine D3 receptor subtype. Bioorg. Med. Chem. Lett. 2004, 14 , 3963-3966.
36. 3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors. Naunyn Schmiedeberg 's Arch. Pharmacol. 2000, 361 , 569-572.
37. Sovago, J.; Farde, L.; Halldin, C.; Langer, O.; Laszlovszky, I.; Kiss, B.; Gulyas, B. Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, C-11 RGH-1756 in the monkey brain. Neurochem. Int. 2004, 45 , 609-617.
38. 18F-labeled dopamine D3 receptor ligands as potential PET imaging agents. Bioorg. Med. Chem. Lett. 2005, 15 , 4819-4823.
39. Leopoldo, M.; Lacivita, E.; De Giorgio, P.; Colabufo, N. A.; Niso, M.; Berardi, F.; Perrone, R. Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D-3 receptors. J. Med. Chem. 2006, 49 , 358-365.
40. Kuhnast, B.; Valette, H.; Besret, L.; Demphel, S.; Coulon, C.; Ottaviani, M.; Guillermier, M.; Bottlaender, M.; Dolle, F. Synthesis and radiolabeling of N -[4-[4- (2-[C-11]methoxyphenyl) piperazin-1-yl]butyl]benzo[b ]thiophene-2- carboxamide, a potential radiotracer for D-3 receptor imaging with PET. Nucl. Med. Biol. 2006, 33 , 785-795.
41. (a) Biswas, S.; Hazeldine, S.; Ghosh, B.; Parrington, I.; Kuzhikandathil, E.; Reith, M. E.; Dutta, A. K. Bioisosteric heterocyclic versions of 7- ([2- (4-phenyl-piperazin-1-yl) ethyl]propylamino) -5,6,7,8-tetrahy-dronaphthalen-2- ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity. J. Med. Chem. 2008, 51 , 3005-3019.
42. (b) Biswas, S.; Zhang, S.; Fernandez, F.; Ghosh, B.; Zhen, J.; Kuzhikandathil, E.; Reith, M. E.; Dutta, A. K. Further structure-activity relationships study of hybrid 7- ([2- (4-phenylpiperazin-1-yl) ethyl]propylamino) -5,6,7, 8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action. J. Med. Chem. 2008, 51 , 101-117.
43. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000, 289 , 739-745.
44. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318 , 1258-1265.
45. Warne, T.; Serrano-Vega, M. J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C; Henderson, R.; Leslie, A. G.; Tate, C. G.; Schertler, G F. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature (London) 2008, 454 , 486-491.
46. Shi, L.; Javitch, J. A. The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. Proc. Natl. Acad. Sci. U. S. A. 2004, 101 , 440-445.
47. Lan, H.; Durand, C. J.; Teeter, M. M.; Neve, K. A. Structural determinants of pharmacological specificity between D (1) and D (2) dopamine receptors. Mol. Pharmacol. 2006, 69 , 185-194.
48. Sokoloff, P.; Giros, B.; Martres, M.-P.; Bouthenet, M.-L.; Schwartz, J.-C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature (London) 1990, 347 , 146-151.
49. Valant, C; Gregory, K. J.; Hall, N. E.; Scammells, P. J.; Lew, M. J.; Sexton, P. M.; Christopoulos, A. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J. Biol. Chem. 2008, 283 , 29312-29321.
50. Siracusa, M. A.; Salerno, L.; Modica, M. N.; Pittala, V.; Romeo, G.; Amato, M. E.; Nowak, M.; Bojarski, A. J.; Mereghetti, I.; Cagnotto, A.; Mennini, T. Synthesis of new arylpiperazinylalkylthiobenzi-midazole, benzothiazole, or benzoxazole derivatives as potent and selective 5-HT1A serotonin receptor ligands. J. Med. Chem. 2008, 51 , 4529-4538.
51. (a) Millan, M. J.; la Cour, C. M.; Novi, F.; Maggio, R.; Audinot, V.; Newman-Tancredi, A.; Cussac, D.; Pasteau, V.; Boutin, J.-A.; Dubuf-fet, T; Lavielle, G. S33138 [N -[4-[2-[(3aS , 9bR ) -8-cyano-1, 3a, 4, 9b-tetrahydro[1]-benzopyrano[3, 4-c ]pyrrol-2 (3H) -yl) -ethyl]phenylaceta-mide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. receptor-binding profile and functional actions at G-protein-coupled receptors. J. Pharmacol. Exp. Ther. 2008, 324 , 587-599.
52. (b) Millan, M. J.; Svenningsson, P.; Ashby, C. R., Jr.; Hill, M.; Egeland, M.; Dekeyne, A.; Brocco, M.; Di Cara, B.; Lejeune, F.; Thomasson, N.; Munoz, C; Mocaer, E.; Crossman, A.; Cistarelli, L.; Girardon, S.; Iob, L.; Veiga, S.; Gobert, A. S33138 [N -[4-[2-[(3aS , 9bR ) -8-cyano-1, 3a, 4, 9b-tetrahydro[1]-benzopyrano[3, 4-c ]pyrrol-2 (3H) -yl) -ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. J. Pharmacol. Exp. Ther. 2008, 324 , 600-611.
53. (c) Millan, M. J.; Loiseau, F.; Dekeyne, A.; Gobert, A.; Flik, G.; Cremers, T. I.; Rivet, J.-M.; Sicard, D.; Billiras, R.; Brocco, M. S33138 (N -[4-[2-[(3aS , 9bR ) -8-cyano-1, 3a, 4, 9b-tetrahydro[1]benzopyrano[3, 4-c ]pyrrol- 2 (3H) -yl) -ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J. Pharmacol. Exp. Ther. 2008, 324 , 1212-1226.
54. Yuan, J.; Chen, X.; Brodbeck, R.; Primus, R.; Braun, J.; Wasley, J. W. F.; Thurkauf, A. NGB 2904 and NGB 2849: two highly selective dopamine D-3 receptor antagonists. Bioorg. Med. Chem. Lett. 1998, 8 , 2715-2718.
55. Wood, M. D.; Boyfield, I.; Nash, D. J.; Jewitt, F. R.; Avenell, K. Y.; Riley, G. J. Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor. Eur. J. Pharmacol. 2000, 407 , 47-51.
56. Wicke, K.; Garcia-Ladona, J. The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors. Eur. J. Pharmaco. 2001, 424 , 85-90.
57. Gyertyan, I.; Kiss, B.; Gal, K.; Laszlovszky, I.; Horvath, A.; Gemesi, L. I.; Saghy, K.; Pasztor, G.; Zajer, M.; Kapas, M.; Csongor, E. A.; Domany, G.; Tihanyi, K.; Szombathelyi, Z. Effects of RGH-237 [N - (4-[4- (3-aminocarbonyl-phenyl) -piperazin-1-yl]-butyl) -4-bromo-benza-mide], an orally active, selective dopamine D-3 receptor partial agonist in animal models of cocaine abuse. J. Pharmacol. Exp. Ther. 2007, 320 , 1268-1278.
58. Chen, J.; Collins, G. T.; Zhang, J.; Yang, C. Y.; Levant, B.; Woods, J.; Wang, S. Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profile. J. Med. Chem. 2008, 51 , 5905-5908.
59. Robarge, M. J.; Husbands, S. M.; Kieltyka, A.; Brodbeck, R.; Thurkauf, A.; Newman, A. H. Design and synthesis of novel ligands selective for the Dopamine D3 receptor subtype. J. Med. Chem. 2001, 44 , 3175- 3186.
60. Newman, A. H.; Cao, J. J.; Bennett, C. J.; Robarge, M. J.; Freeeman, R. A.; Luedtke, R. R. N - (4-[4- (2, 3-Dichlorophenyl) piperazin-1-yl]butyl, butenyl and butynyl) arylcarboxamides as novel dopamine D-3 receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13 , 2179-2183.
61. Cruickshank, P. A.; Fishman, M. Studies in alkylation. 2. Reactions of epoxyalkyl bromides. J. Org. Chem. 1969, 34 , 4060-4065.
62. Hackling, A.; Ghosh, R.; Perachon, S.; Mann, A.; Holtje, H. D.; Wermuth, C. G.; Schwartz, J. C; Sippl, W.; Sokoloff, P.; Stark, H. N - (w - (4- (2-methoxyphenyl) piperazin-1-yl) alkyl) carboxamides as dopamine D2 and D3 receptor ligands. J. Med. Chem. 2003, 46 , 3883-3899.
63. Chu, W. H.; Tu, Z.; McElveen, E.; Xu, J. B.; Taylor, M.; Luedtke, R. R.; Mach, R. H. Synthesis and in vitro binding of N -phenyl piperazine analogs as potential dopamine D-3 receptor ligands. Bioorg. Med. Chem. 2005, 13 , 77-87.
64. SHELXTL , version 6.14; Bruker AXS Inc., Madison, WI, 2000.
65. Flack, H. D. On enantiomorph-polarity estimation. Acta Crystallogr. A 1983, 39 , 876-881.